Ceroid Lipofuscinosis, Neuronal 5 Clinical Trial
Official title:
A Natural History and Outcome Measure Discovery Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)
| NCT number | NCT03822650 |
| Other study ID # | CLN-100 |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | March 13, 2019 |
| Est. completion date | January 2026 |
CLN5 is a form of Batten Disease, a neurodegenerative disorder in children causing psychomotor regression, seizures, blindness, loss of ambulation and premature death, and has no available treatments. The purpose of this study is to investigate the clinical characteristics and natural clinical progression of symptoms in individuals with CLN5. This natural history study is important to better understand disease course to be able to determine clinically relevant outcome measures for use in future clinical trials.
| Status | Recruiting |
| Enrollment | 30 |
| Est. completion date | January 2026 |
| Est. primary completion date | January 2026 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: 1. Age at disease onset of = 5 years of age. 2. Molecular genetic diagnosis confirming the presence of pathogenic or likely pathogenic variant(s) on both alleles (biallelic) of the CLN5 gene. For Prospective Arm only: 1. Subject age of = 9 years. 2. Hamburg motor and vision score of = 1 at time of consent. 3. Subject must have a caregiver available to support the subject and attend visits with the subject. Exclusion Criteria - All Subjects: 1. Has another neurologic disease or illness that may have caused cognitive decline before study entry. 2. Has a known pathogenic or clinically suspected mutation in a seizure associated genetic mutation besides CLN5. 3. Any prior participation in a study in which a gene therapy vector or stem cell transplantation was administered. 4. Participation in other investigational studies and non-interventional studies that have similar study assessments as this protocol while the subject is enrolled in this study is prohibited. |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Rochester Medical Center | Rochester | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Neurogene Inc. |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Unified Batten Disease Rating Scale (UBDRS) | Disease-specific clinical assessment used to assess physical, seizure, behavioral and functional capabilities. For physical assessments scores range from 0 to 4 with the score of 4 being most severe. | 3 years | |
| Primary | Late Infantile Neuronal Ceroid Lipofuscinosis Rating Scale (Hamburg Scale) | Disease specific tool used to capture 4 domains including motor function, seizures, visual function and language. Each sub-scale can be scored from 0-3 points in which 0 represents loss of function. | 3 years | |
| Secondary | Electroencephalography (EEG) | EEG records electrical brain activity and Interictal discharges (location, focal/generalized, etc) will be compared to baseline and characterized over time. | 3 years | |
| Secondary | Vineland Adaptive Behavior Scale, 2nd Edition (Vineland-II) | Standard assessment measuring communication, socializing, and daily living skills to assess their overall adaptive functioning for individuals up to 90 years of age. A higher score generally corresponds with higher adaptive function. | 3 years | |
| Secondary | Caregiver Global Impression of Change (CaGI-C) | The CaGI-C is a caregiver reported outcome measure designed to assess any change in the subject's presentation over the preceding 7 days, as compared to the previous visit. | 3 years |